
Kate Haviland: The Bilingual Biotech Leader Behind Blueprint's $9.5B Sanofi Deal
In this episode I am joined by Kate Haviland, who most recently served as President and CEO of Blueprint Medicines, guiding it from a clinical-stage company through a fully integrated commercial business and ultimately t




















